NCT04482595View on ClinicalTrials.gov

BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

July 31, 2024

Study Completion Date

April 30, 2025

Conditions
COVID-19Long COVIDPulmonary FibrosisPost-acute Respiratory Complications of COVID-19
Interventions
DRUG

BIO 300 Oral Suspension

Suspension of genistein nanoparticles

DRUG

Placebo

Matched placebo for BIO 300 Oral Suspension

Trial Locations (4)

10016

NYU Langone Health, New York

77030

University of Texas Health Science Center at Houston, Houston

77210

Houston Methodist Research Institute, Houston

80045

University of Colorado Anschutz Medical Campus, Aurora

Sponsors
All Listed Sponsors
collaborator

NYU Langone Health

OTHER

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Humanetics Corporation

INDUSTRY

NCT04482595 - BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients | Biotech Hunter | Biotech Hunter